{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1382825894688558993.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Kerry Taylor"}],"foaf:familyName":[{"@value":"Taylor"}],"foaf:givenName":[{"@value":"Kerry"}]}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1362825894688558976","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1016/s0140-6736(17)31266-7"},{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0140673617312667?httpAccept=text/xml"},{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0140673617312667?httpAccept=text/plain"}],"notation":[{"@value":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/s0140-6736(17)31266-7_KK5IXHj2mkhYd8ROk8dDM2RYheN"}]}